Pioglitazone Decreases Plasma Cholesteryl Ester Transfer Protein Mass, Associated With a Decrease in Hepatic Triglyceride Content, in Patients With Type 2 Diabetes by Jonker, Jacqueline T. et al.
Pioglitazone Decreases Plasma Cholesteryl
Ester Transfer Protein Mass, Associated
With a Decrease in Hepatic Triglyceride
Content, in Patients With Type 2 Diabetes
JACQUELINE T. JONKER, MD
1
YANAN WANG, MSC
1
WILLEKE DE HAAN, PHD
1
MICHAELA DIAMANT, MD, PHD
2
LUUK J. RIJZEWIJK, MD
2
RUTGER W. VAN DER MEER, MD, PHD
3
HILDO J. LAMB, MD, PHD
3
JOUKE T. TAMSMA, MD, PHD
4
ALBERT DE ROOS, MD, PHD
3
JOHANNES A. ROMIJN, MD, PHD
1
PATRICK C.N. RENSEN, PHD
1,4
JOHANNES W.A. SMIT, MD, PHD
1
OBJECTIVE — Thiazolidinediones reduce hepatic steatosis and increase HDL cholesterol
levels. In mice with human-like lipoprotein metabolism (APOE*3-Leiden.CETP transgenic
mice), a decrease in hepatic triglyceride content is associated with a decrease in plasma cho-
lesteryl ester transfer protein (CETP) mass and an increase in HDL levels. Therefore, the aim of
the present study was to assess the effects of pioglitazone on CETP mass in patients with type 2
diabetes.
RESEARCH DESIGN AND METHODS — We included 78 men with type 2 diabetes
(aged 56.5  0.6 years; HbA1c 7.1  0.1%) who were randomly assigned to treatment with
pioglitazone (30 mg/day) or metformin (2000 mg/day) and matching placebo, in addition to
glimepiride.Atbaselineandafter24weeksoftreatmentplasmaHDLcholesterollevelsandCETP
mass were measured, and hepatic triglyceride content was assessed by proton magnetic reso-
nance spectroscopy.
RESULTS — Pioglitazone decreased hepatic triglyceride content (5.9 [interquartile range
2.6–17.4] versus 4.1 [1.9–12.3]%, P  0.05), decreased plasma CETP mass (2.33  0.10 vs.
2.06  0.10 g/ml, P  0.05), and increased plasma HDL cholesterol level (1.22  0.05 vs.
1.340.05mmol/l,P0.05).Metformindidnotsigniﬁcantlychangeanyoftheseparameters.
CONCLUSIONS — A decrease in hepatic triglyceride content by pioglitazone is accompa-
nied by a decrease in plasma CETP mass and associated with an increase in HDL cholesterol
levels. These results in patients with type 2 diabetes fully conﬁrm recent ﬁndings in mice.
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epaticsteatosisisaprevalentcondi-
tioninpatientswithtype2diabetes
and is associated with an increased
cardiovascular risk (1,2). Furthermore,
many patients with type 2 diabetes dis-
play dyslipidemia characterized by high
plasma levels of apolipoprotein (apo) B-
lipoproteins and triglycerides and low
plasma levels of HDL cholesterol. Re-
cently, Toledo et al. (3) showed that he-
patic steatosis is associated with more
severe hyperlipidemia in type 2 diabetes,
which might contribute to the increased
risk of cardiovascular disease.
To reduce this increased cardiovas-
cular risk in type 2 diabetes, regular
treatment algorithms include lipid-
lowering drugs. Our previous studies in
APOE*3-Leiden.CETP transgenic mice,
a well-established model for human-
like lipoprotein metabolism, showed
that treatment with either statins (4),
ﬁbrates (5), or niacin (6) resulted in a
reduction in plasma apoB-lipoproteins
and triglyceride levels and an increase
in HDL cholesterol. Moreover, these
treatments reduced hepatic lipid con-
tent (i.e., both triglycerides and choles-
terol) as well as the hepatic expression
and plasma levels of cholesteryl ester
transfer protein (CETP) (4–6). CETP is
a protein that mediates the heteroex-
change of cholesteryl esters from HDL
to (V)LDL with a simultaneous ex-
change of triglycerides from (V)LDL to
HDL. These studies thus suggest that
lowering of hepatic lipid content in
APOE*3-Leiden.CETP mice increased
HDL cholesterol levels by reduction of
plasma CETP mass.
Because the correlation between he-
patic triglyceride content and plasma
CETP mass has not been studied in hu-
mans, the aim of this study was to evalu-
ate whether the relationship between
lowering of hepatic triglyceride content
and decreased plasma CETP mass also
exists in humans. Hepatic triglyceride
content can be lowered by thiazoli-
dinediones, including pioglitazone (7).
Indeed, in a previous study, we reported
that both antidiabetic drugs pioglitazone
andmetforminimprovedinsulinsensitiv-
ity in men with type 2 diabetes whereas
onlypioglitazonereducedhepatictriglyc-
eridecontent(8).Therefore,weusedpio-
glitazone treatment as a model to study
the effects of a change in hepatic triglyc-
eride content on CETP mass in patients
with type 2 diabetes and used metformin
treatment as a negative control.
RESEARCH DESIGN AND
METHODS— This study used the
data from the Pioglitazone Inﬂuence on
tRriglyceride Accumulation in the Myo-
cardium in Diabetes (PIRAMID) study.
Thiswasaprospective,randomized,dou-
ble-blind, intervention study, which
compared the effects of pioglitazone and
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tabolism. The results were reported pre-
viously (8), and the study design will be
summarizedhere.Thestudyincludedmale
patients with type 2 diabetes without car-
diovascular disease or diabetes-related
complications. Inclusion criteria were BMI
25–32kg/m
2,agebetween45and65years,
and diabetes well controlled with met-
formin, a sulfonylurea, or both (HbA1c
6.5–8.5%). Patients were excluded on the
following criteria: uncontrolled hyperten-
sion (blood pressure150/85 mmHg),
medical history of diabetes-related compli-
cations, liver disease, cardiovascular dis-
ease, or use of thiazolidinediones or insulin
beforethestudy.Thisstudywasexecutedat
two hospitals in the Netherlands (Leiden
University Medical Center, Leiden, and VU
University Medical Center, Amsterdam),
and both local ethics committees gave their
approval. All participants signed informed
consent.
If patients met the inclusion criteria,
their glucose-lowering medication was
switchedtoglimepiridemonotherapy,until
a stable dose was reached 2 weeks before
thestartoftheintervention.Atbaseline,pa-
tients were randomly assigned to met-
formin (500 mg twice daily, titrated to
1,000 mg twice daily) or pioglitazone
(15 mg once daily, titrated to 30 mg
once daily after 2 weeks) in addition to
glimepiride. In both the metformin and
pioglitazone groups, 39 patients were
included. In the pioglitazone group 34
patients and in the metformin group 37
patients completed the study.
Patients were studied at baseline and
after 24 weeks of treatment. Blood sam-
pling and magnetic resonance spectros-
copy were performed after an overnight
fast.
Hepatic triglyceride content
Hepatic triglyceride content was mea-
sured by proton (
1H) magnetic resonance
spectroscopy on a 1.5-T whole-body
magnetic resonance scanner (Gyroscan
ACS/NT15; Philips, Best, the Nether-
lands). The technical details were de-
scribed previously (8). The voxel was
placed in the hepatic parenchyma, care-
fully preventing placement in vascular
structures. Java Magnetic Resonance User
interfacesoftware(jMRUIversion2.2;de-
veloped bij A. van den Boogart, Katholieke
Universiteit Leuven, Leuven, Belgium) was
used for ﬁtting of the spectra. Technical
details of spectra acquisition and spectra
quantiﬁcation were described previously
(8,9). Spectra with and without water
suppression were acquired to calculate
hepatic triglyceride content relative to
water (signal amplitude of triglyceride/
signal amplitude of water  100%).
Plasma cholesterol, triglyceride,
apoB100, and CETP mass analyses
All plasma samples were obtained in the
postabsorptive state on the day of ran-
domizationandat24weeksandanalyzed
in one laboratory (Leiden, the Nether-
lands). To ascertain that we could make
adequate correlations, these measure-
ments were performed in the same blood
samples. Plasma triglyceride and choles-
terol concentrations were determined
using commercially available enzymatic
kits (1488872 and 236691; Roche Mo-
lecular Biochemicals, Indianapolis, IN).
This cholesterol assay was also used for
determination of plasma HDL cholesterol
after precipitation of apoB-lipoproteins
from 20 l of plasma by adding 10 lo f
heparin (500 units/ml; LEO Pharma, The
Netherlands) and 10 l of 0.2 mol/l
MnCl2 (6). Plasma apoB100 was deter-
mined with a Human ApoB ELISA kit
(3715–1H; Mabtech, Nacka Strand, Swe-
den). The plasma CETP mass was quanti-
ﬁed using a CETP ELISA Daiichi kit
(Daiichi Pure Chemicals, Tokyo, Japan).
Statistics
Data are expressed as means  SEM or as
median (interquartile range) because he-
patic triglyceride content and plasma tri-
glycerides were not normal distributed.
Paired t tests or Wilcoxon signed-rank
tests were used for within-group differ-
ences. We used ANOVA to assess be-
tween-group differences. For correlation
analysis, Spearman correlation analyses
were used. We used SPSS software (ver-
sion 16.0; SPSS, Chicago, IL) for statisti-
cal analyses. P  0.05 was considered
statistically signiﬁcant.
RESULTS— At baseline, patients in
both treatment groups were well-matched
forage(pioglitazone56.81.0yearsand
metformin 56.4  0.9 years, between-
group P  0.05), duration of diabetes
(pioglitazone 4 [3–6] years and met-
formin 3 [1–5] years, P  0.05), and BMI
(pioglitazone 28.2  0.5 kg/m
2 and met-
formin29.30.6kg/m
2,between-group
P  0.05) (8).
Treatment effect
The effects of treatment on hepatic tri-
glyceride content and plasma lipid pro-
ﬁles are presented in Table 1. As we
showed before (8), treatment with piogli-
tazonefor24weeksdecreasedhepatictri-
glyceride content (5.9 [2.6–17.4] vs. 4.1
[1.9–12.3]%,P0.05).Thiswasaccom-
panied by a decrease in plasma CETP
mass(2.330.10vs.2.060.10g/ml,
P  0.05) and an increase in plasma total
cholesterol (4.90  0.16 vs. 5.19  0.22
mmol/l, P  0.05), which was explained
in part by an increase in HDL cholesterol
levels (1.22  0.05 vs. 1.34  0.05
mmol/l, P  0.05). Treatment with met-
formindidnotsigniﬁcantlyaffecteitherof
these parameters. Treatment with piogli-
tazone and metformin both decreased
plasma triglycerides and apoB100 signif-
icantly; however, there was no difference
Table1—Hepatictriglyceridecontent,plasmaCETPmass,cholesterol,triglycerides,andapoB100atbaselineandafter24weeksoftreatment
Pioglitazone Metformin P value between
groups Baseline 24 weeks Baseline 24 weeks
Hepatic triglyceride content (%)* 5.9 (2.6–17.4) 4.1 (1.9–12.3)† 7.7 (3.7–23.9) 10.7 (5.1–22.0)  0.01
CETP mass (g/ml) 2.33  0.10 2.06  0.10† 2.44  0.08 2.24  0.12 NS
HDL cholesterol (mmol/l) 1.22  0.05 1.34  0.05† 1.22  0.06 1.23  0.06 0.02
Total cholesterol (mmol/l) 4.90  0.16 5.19  0.22† 5.15  0.18 4.99  0.18  0.01
Triglycerides (mmol/l) 1.74 (0.97–3.09) 1.37 (0.88–1.80)† 2.08 (1.08–2.74) 1.23 (0.68–1.92)† NS
ApoB100 (mg/dl) 84.88  5.08 75.41  4.03† 89.72  5.01 74.58  4.22† NS
Data are means  SEM or median (interquartile range). *Data from van der Meer et al. (8). †Within group P  0.05.
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Correlations
Changes in plasma CETP mass after 24
weeksinthepioglitazone-treatedpatients
correlatedwithchangesinhepatictriglyc-
eride content (r  0.34, P  0.05), al-
thoughthisassociationwasnotpresentin
the metformin group.
Effect of statin use in the
pioglitazone-treated group
In the pioglitazone group, 19 of the 39
patients used a statin at the start of the
study. Table 2 compares the changes in
lipid levels and hepatic triglyceride con-
tent between statin users versus nonstatin
users in the patients treated with pioglita-
zone. In nonstatin users, pioglitazone de-
creased liver triglyceride content (6.4
[2.5–18.9] vs. 4.9 [1.9–14.7]%, P 
0.05), increased HDL cholesterol levels
(1.140.06vs.1.320.06mmol/l,P
0.05), and decreased CETP mass (2.64 
0.14 vs. 2.16  0.12 g/ml, P  0.05).
However,remarkably,instatinusers,pio-
glitazone also reduced liver triglyceride
content (8.0 [2.8–16.5] versus 3.7 [1.9–
10.9]%, P  0.05), but did not affect ei-
ther HDL cholesterol or CETP mass.
ApoB100 decreased signiﬁcantly only in
thestatinusers(83.078.29vs.68.77
5.34 mg/dl, P  0.05).
CONCLUSIONS — In this study, we
assessed the associations among changes
in hepatic triglyceride content, plasma
CETP mass, and lipid proﬁles in patients
with type 2 diabetes. The results show
that pioglitazone decreased hepatic tri-
glyceride content, associated with de-
creasedplasmaCETPmass,andincreased
HDLcholesterollevels.Theseﬁndingsare
in full concordance with our recent stud-
ies in APOE*3-Leiden.CETP mice, which
showed that classic lipid-lowering drugs
concurrently lowered hepatic lipid con-
tent and decreased hepatic CETP mRNA
expression, resulting in decreased plasma
CETP mass (4–6).
Inthisstudy,plasmatriglyceridesand
plasma apoB100 decreased equivalently
in both the pioglitazone and metformin
group. Accordingly, other studies have
shown that pioglitazone and metformin
both decrease plasma triglycerides (10–
13). Given the generally observed inverse
relationship between plasma triglycerides
and HDL cholesterol found in epidemio-
logical studies, a decrease in plasma tri-
glyceridesmayinduceanincreaseinHDL
cholesterol only. However, in the present
study the decrease in plasma triglycerides
was not different between the groups and
plasmaHDLcholesterolonlyincreasedin
the pioglitazone group, indicating that
another mechanism may be responsible
forelicitingthisdifference,i.e.,thereduc-
tion in CETP.
It is intriguing to speculate on the
mechanism underlying the correlation
betweenhepaticlipidcontentandplasma
CETP mass. It is known that cholesterol
derivatives are agonists for the nuclear re-
ceptor liver X receptor  (LXR). Activa-
tion of LXR results in increased
transcription of CETP and sterol regula-
tory element-binding proteins-1c (14).
Thus, our studies in APOE*3-Leiden-
.CETP mice suggest that a decrease in he-
patic cholesterol content, associated with
a decrease in cholesterol derivatives, such
as oxysterols, reduces LXR activation,
thereby further downregulating CETP
mRNA transcription. It is therefore likely
that in our study pioglitazone decreased
hepatic cholesterol content in addition to
triglyceride content, thereby downregu-
lating LXR-activity. Although it is not
possible at this time to noninvasively
measure hepatic cholesterol content in
humans, studies in APOE*3-Leiden-
.CETP mice with a human-like protein
proﬁle generally demonstrate a strong re-
lation between hepatic cholesterol and
hepatic triglyceride content.
Notably, thiazolidinediones such as
pioglitazone, can also upregulate LXR
expression via activation of peroxisome
proliferator-activated receptor-, which
is most dominantly expressed in adipose
tissue(15).Moreover,CETPexpressionis
prominent in adipose tissue. Radeau et al.
(16) have shown that CETP mRNA ex-
pression in adipose tissue correlates with
plasma CETP concentrations. The in-
creasedsubcutaneousfatmassasinduced
by pioglitazone treatment may contribute
to increased plasma CETP levels, thereby
potentially counteracting the decrease in
plasmaCETPlevelsduetothedecreasein
hepatic lipid content by pioglitazone.
Therefore, the observed decrease in
plasma CETP mass due to the decrease in
hepatic triglyceride content may, in fact,
be larger.
To our knowledge, only one other
study evaluated the effect of thiazoli-
dinediones on CETP expression, but the
hepatic triglyceride content was not stud-
ied. Chappuis et al. (17) performed a
crossover study comparing pioglitazone
versus rosiglitazone in 17 patients with
type 2 diabetes. They found that rosigli-
tazone increased total cholesterol levels
anddecreasedplasmaCETPactivityinac-
cordance with our study. However, pio-
glitazone did not have any effect on these
parameters. The differences in their re-
sults on the effects of pioglitazone com-
pared to our study may be due to the
shorter treatment duration of 12 weeks
and/or to the smaller sample size in the
previous study.
Finally, we found that pioglitazone
did not further decrease CETP mass in
patients who already used a statin. Exper-
imental studies in APOE*3-Leiden.CETP
mice have demonstrated that statins de-
crease plasma CETP mass by decreasing
Table 2—Hepatic triglyceride content, plasma CETP mass, cholesterol, triglycerides, and apoB100 in patients treated with pioglitazone,
selected on the use of statins at baseline
No statin use Statin use P value between
groups Baseline 24 weeks Baseline 24 weeks
Hepatic triglyceride content (%) 6.4 (2.5–18.9) 4.9 (1.9–14.7)* 8.0 (2.8–16.5) 3.7 (1.9–10.9)* NS
CETP mass (g/ml) 2.64  0.14 2.16  0.12* 1.98  0.09 1.96  0.15 0.03
HDL cholesterol (mmol/l) 1.14  0.06 1.32  0.06* 1.30  0.06 1.36  0.08 NS
Total cholesterol (mmol/l) 5.32  0.22 5.87  0.35 4.44  0.19 4.55  0.19 NS
Triglycerides (mmol/l) 1.74 (0.82–3.11) 1.32 (0.80–3.02) 1.61 (1.02–2.41) 1.46 (0.99–1.69) NS
ApoB100 (mg/dl) 86.59  6.22 82.06  5.77 83.07  8.29 68.77  5.34* NS
Data are means  SEM or median (interquartile range). *Within group P  0.05.
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to decreased hepatic cholesterol content
(4). Apparently the effect of statins is
dominant over the effect of pioglitazone.
We hypothesize that statins speciﬁcally
decrease hepatic cholesterol content and
downregulate CETP mRNA expression.
Therefore, additional lowering of hepatic
triglyceride content will not result in an
additional decrease in CETP expression.
However, the current study was not de-
signed to assess the effects of statins on
these parameters.
A limitation of this study is that only
men were included. Kinoshita et al. (18)
showed that men have lower CETP activ-
ity than women; thus, these data may not
be readily extrapolated to women with
type 2 diabetes.
In summary, this study shows that in
male patients with type 2 diabetes a de-
crease in hepatic triglyceride content by
pioglitazone is associated with a decrease
in CETP mass and an increase in HDL
cholesterol levels. Furthermore, we con-
ﬁrmed that use of statins is associated
withadecreasedplasmaCETPmass.Both
ﬁndings are in full agreement with our
recent ﬁndings in APOE*3-Leiden.CETP
mice and support the validity of these
mice as a model for human-like lipopro-
tein metabolism.
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